Lieb, W., Safa, R., Benjamin, E.J., Xanthakis, V., Yin, X., Sullivan, L.M., Larson, M.G., Smith, H.M., Vita, J.A., Mitchell, G.F., Sawyer, D.B. and Vasan, R.S. (2009) Vascular Endothelial Growth Factor, Its Soluble Receptor, and Hepatocyte Growth Factor: Clinical and Genetic Correlates and Association with Vascular Function. European Heart Journal, 30, 1121-1127.
http://www.ncbi.nlm.nih.gov/pubmed/19223316
http://dx.doi.org/10.1093/eurheartj/ehp007

has been cited by the following article:

• TITLE: Follistatin, a Novel Biomarker for Malignant Gliomas

  AUTHORS: Elvira Lekka, Nicolas Tsesmetzis, Katherine M. Ashton, Peter Abel, Charles Davies, Gregory Hall, Timothy Dawson, Robert W. Lea

  KEYWORDS: Serum, Malignant Gliomas, Follistatin, Biomarker, Cancer

  JOURNAL NAME: Neuroscience and Medicine, Vol.6 No.3, September 8, 2015

  ABSTRACT: Molecular biomarkers are commonly used for the management of several types of malignant tumours in routine clinical practice. However, this is not the case for malignant gliomas. Cytokines and Angiogenesis factors are potential candidates due to their intrinsic role in tumourigenesis. Pre- and post-operative serum from 36 malignant glioma patients and 36 controls was analysed using the Bio-Plex Pro Angiogenesis and Cytokines Assay (Bio-Rad, USA). Amongst the molecules tested, the serum concentration of follistatin was significantly higher in patients than in controls. Moreover, the serum concentration of follistatin of the patients postoperatively was significantly reduced compared to that preoperatively. Factors such as age and gender did not affect the concentrations of follistatin measured in the serum of patients pre- and post-operatively as well as healthy controls. This is the first report of follistatin as potential biomarker for the detection of malignant gliomas.